Cyclizine Pregnancy and Breastfeeding Warnings
Cyclizine Pregnancy Warnings
In a study 111 mothers given cyclizine during the first trimester for the control of nausea and vomiting, no increase in the incidence of malformations was noted. In addition, other phenothiazine-type agents used for nausea, including prochlorperazine and meclizine, were not associated with malformations. One review of 1125 women who took cyclizine during the first trimester noted five cleft palates amongst the offspring of this group. The incidence of cleft palate among babies born to 24,208 mothers not receiving cyclizine was 19, indicating an approximate five-fold increase in cleft palates among cyclizine users. However, the incidence of cleft palate was similar in patients with nausea and vomiting not treated with cyclizine, indicating the condition itself may be to blame. A review of prenatal drug use in 3026 women with premature infants demonstrated an increased risk of retrolental fibroplasia with antihistamine use during the last two weeks of pregnancy. The dosage used or the particular antihistamine was not specified. The incidence of retrolental fibroplasia in premature infants exposed in utero to antihistamine during this time was 21% compared to 11% in premature infants not exposed.
Cyclizine has been assigned to pregnancy category B by the FDA. Although cyclizine has been shown to be teratogenic in animals, a study of cyclizine use in the first trimester of human pregnancy found no increase in the rate of malformations. Cyclizine is only recommended for use during pregnancy when benefit outweighs risk.
Cyclizine Breastfeeding Warnings
There are no data on the excretion of cyclizine into breast milk.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.